CytRx Corporation CYTR, a biopharmaceutical research and development
company specializing in oncology, announced that the independent Data Safety
Monitoring Committee (DSMC) overseeing the Company's international Phase 2b
clinical trial with aldoxorubicin as a first-line treatment for patients with
late-stage metastatic soft tissue sarcoma has recommended conducting the
clinical trial through completion. This Phase 2b trial allows for a
head-to-head clinical comparison of the commonly used chemotherapeutic agent
doxorubicin with aldoxorubicin, CytRx's tumor-targeting doxorubicin conjugate.
Doxorubicin is dose-limited at a level below its maximum anti-tumor
capabilities due to toxicity, including cardiotoxicity. Data from the Phase 2b
trial is expected in the second half of 2013.
“The recommendation to complete the Phase 2b trial indicates that the DSMC
found no significant safety issues with aldoxorubicin, even though the dose of
aldoxorubicin administered in this trial delivers doxorubicin at
three-and-a-half times its standard dose,” said CytRx CEO Steven A. Kriegsman.
“The DSMC was not charged with evaluating efficacy at this point in the study.
Aldoxorubicin combines doxorubicin with our proprietary linker technology.
This platform technology includes a single molecule that, when attached to a
chemotherapeutic agent, allows for concentration of the agent at the tumor
site, thus allowing for greater drug infusion into the tumor. We believe that
safely concentrating more drug at the tumor site could improve the drug's
effectiveness.
“Aldoxorubicin is the first drug we are evaluating in the clinic based on the
linker technology. Doxorubicin was selected for evaluation as it is well-known
and has been used by the medical community for decades; however the linker has
broad potential utility with proven affinity to couple with multiple
chemotherapeutic agents including paclitaxel, docetaxel, cisplatin, irinotecan
and methotrexate. Each of these agents may be incorporated into our future
clinical development plans,” he added.
The Phase 2b trial is enrolling a total of 105 patients with metastatic,
locally advanced or unresectable soft tissue sarcomas who have not been
previously treated with any chemotherapy and are ineligible for surgery.
Patients in the trial are randomized into two groups, with twice as many
receiving aldoxorubicin as doxorubicin. The trial's primary objective is to
compare progression-free survival between each group. Secondary endpoints
include evaluating tumor response and overall patient survival, and assessing
the safety of aldoxorubicin compared with doxorubicin in this patient
population through a number of indicators, including the frequency and
severity of adverse events. Patients are being enrolled in clinical sites in
the U.S., Hungary, Romania, Russia, Ukraine, India and Australia.
CytRx holds exclusive worldwide rights to aldoxorubicin, as well as option
rights to the protein-binding platform technology that serves as the linker
with doxorubicin.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in